Introduction
Rectal mucosal prostaglandin synthesis is increased in active ulcerative colitis (Sharon et al., 1978; Harris, Smith and Swan, 1978) . The possibility that this change could be of pathogenetic importance has led to the proposal that patients with active disease might benefit from treatment with those of the non-steroidal anti-inflammatory agents which inhibit prostaglandin synthesis. In this report, however, 4 patients with quiescent proctocolitis are described in whom oral administration of such drugs for painful disorders appeared to precipitate relapse. Because this effect can be prevented, at least in experimental animals, by pretreatment with prostaglandins, it has been suggested that such ulceration is related to drug-induced mucosal prostaglandin deficiency, and that these ubiquitous fatty acids may play a cytoprotective role in the stomach and small intestine (Robert, 1979 (Kimberg, 1978; Sharon et al., 1978) . Indeed, these observations suggest that, as in the upper gastrointestinal tract, prostaglandins could be cytoprotective in the large bowel, a function which would be consistent with the theory that sulphasalazine maintains remission in quiescent colitis by inhibiting degradation, rather than synthesis, of mucosal prostaglandins (Hoult and Moore, 1978 (Cockbill, Heptinstall and Taylor, 1979) ; more speculatively, they could also lead to mucosal damage by enhancing synthesis of products of the lipoxygenase enzyme system (Moncada and Vane, 1979 
